Related Experiment Video
Updated: Feb 9, 2026

Visualizing Dengue Virus through Alexa Fluor Labeling
Published on: July 9, 2011
The Development of Peptide-based Antimicrobial Agents against Dengue Virus
Yen-Wei Huang1,2, Chun-Ting Lee1,3, Ta-Chen Wang1,2
1The School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.
Abstract:
Dengue fever has become an imminent threat to international public health because of global warming and climate change. The World Health Organization proclaimed that more than 50% of the world's population is at risk of dengue virus (DENV) infection. Therefore, developing a clinically approved vaccine and effective therapeutic remedy for treating dengue fever is imperative. Peptide drug development has become a novel pharmaceutical research field. This article reviews various peptidesbased antimicrobial agents targeting three pathways involved in the DENV lifecycle. Specifically, they are peptide vaccines from immunomodulation, peptide drugs that inhibit virus entry, and peptide drugs that interfere with viral replication. Many antiviral peptide studies against DENV have been conducted in animal model trials, and progression to clinical trials for these promising peptide drugs is anticipated.
More Related Videos
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Peptide Bonds
Antimicrobial Effectiveness
What are Viruses?
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Subviral Agents

